Floatz logo

FLUOROURACILUM

Gastric Neoplasm

Seagen, a wholly owned subsidiary of PfizerSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Gastric Neoplasm cohort.

Asset / SponsorPhaseRating
Capecitabine
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 3BB
Eloxatin
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Jazz Pharmaceuticals
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →